|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, June 21, 2017 ) Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) - Mitogen-activated protein kinase kinase kinase 7 is an enzyme that is encoded by the MAP3K7 gene. It plays an important role in the cascades of cellular responses evoked by changes in the environment.
Report Highlights
According to the recently published report 'Mitogen Activated Protein Kinase Kinase Kinase 7 - Pipeline Review, H1 2017'; Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.
Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) - Mitogen-activated protein kinase kinase kinase 7 is an enzyme that is encoded by the MAP3K7 gene. It plays an important role in the cascades of cellular responses evoked by changes in the environment. It mediates signal transduction of TRAF6, various cytokines interleukin-1 (IL-1) , transforming growth factor-beta (TGFB) , TGFB-related factors like BMP2 and BMP4, toll-like receptors (TLR) , tumor necrosis factor receptor CD40 and B-cell receptor (BCR) .
The report 'Mitogen Activated Protein Kinase Kinase Kinase 7 - Pipeline Review, H1 2017' outlays comprehensive information on the Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviewsalso reviews key players involved in Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical and Discovery stages are 2 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Genetic Disorders and Ophthalmology which include indications Inflammation, Chronic Inflammation, Neonatal Onset Multisystem Inflammatory Disease, Ovarian Cancer, Pancreatic Cancer and Proliferative Vitreoretinopathy (PVR) .
For more information about this report at http://www.reportsweb.com/mitogen-activated-protein-kinase-kinase-kinase-7-pipeline-review-h1-2017
Report Scope
- The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25)
- The report reviews Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) targeted therapeutics and enlists all their major and minor projects
- The report assesses Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) targeted therapeutics
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001834426/sample
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles
Astellas Pharma Inc
Chugai Pharmaceutical Co Ltd
Confluence Life Sciences Inc
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001834426/discount
List of Tables
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indication, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products under Investigation by Universities/Institutes, H1 2017
Products under Investigation by Universities/Institutes, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by Astellas Pharma Inc, H1 2017
Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017
Pipeline by Confluence Life Sciences Inc, H1 2017
Dormant Projects, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001834426/buy/3500
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
